Skip to main content

What is the difference between Truxima and Rituxan?

Medically reviewed by Kristianne Hannemann, PharmD. Last updated on March 25, 2025.

Official answer

by Drugs.com

Truxima (rituximab-abbs) is a biosimilar to Rituxan (rituximab). While both drugs are CD20-directed cytolytic antibodies used to treat non-Hodgkin’s lymphoma (NHL), Rituxan has additional FDA-approved indications beyond NHL.

What Is a Biosimilar?

Biosimilars are highly similar to an already-approved biological product and have no clinically meaningful differences in terms of safety, purity, and potency.

FDA-Approved Uses: Truxima vs. Rituxan

Truxima and Rituxan belong to the class of drugs called CD20-directed cytolytic antibodies.

Both medications are approved for the treatment of adult patients with non-Hodgkin’s lymphoma (NHL):

  • Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent.
  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.
  • Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
  • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or other anthracycline-based chemotherapy regimens.

Rituxan is additionally indicated for several other medical conditions in adults patients, including:

  • Chronic Lymphocytic Leukemia (CLL):
    • Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC).
  • Rheumatoid Arthritis (RA):
    • In combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies.
  • Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)
    • in combination with glucocorticoids inpatients two years of age and older.
  • Pemphigus Vulgaris (PV):
    • Moderate to severe disease in adult patients.

It is also approved to treat children 6 years and older with mature B-cell NHL and mature B-cell acute leukemia.

For more information, see What Are Biosimilars? Top Facts You May Not Know

Related questions

References

Read next

How long does it take for Rituxan to work?

Patients treated with Rituxan may notice an early response within 7-8 weeks of treatment. Most rheumatoid arthritis patients will notice some improvement in their symptoms, such as improvement in their levels of pain and inflammation, within 16 weeks of starting treatment with Rituxan. Continue reading

What are biosimilar drugs and how do they compare to biologics?

A biosimilar is a biological product that is similar to a reference biologic (usually the originally approved product) and for which there are no clinically meaningful differences in terms of safety, purity, and potency. One example is Amjevita (adalimumab-atto), the first biosimilar approved for Humira (adalimumab) in 2016.

Continue reading

Does Rituxan cause hair loss?

It’s possible for Rituxan (rituximab) to cause hair loss. This includes losing hair anywhere on your body, such as your head, legs, eyebrows, and eyelashes. Hair loss (alopecia) does not seem to be a common side effect of Rituxan. Continue reading

Related medical questions

Drug information

Related support groups